Corcept Therapeutics Inc
CORT
查看详细走势图
40.830USD
+2.470+6.44%
收盘 02/06, 16:00（美东）报价延迟15分钟
4.29B总市值
39.97市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.44%
5天
+2.41%
1月
+10.35%
6月
-42.88%
今年开始到现在
+17.33%
1年
-39.96%
查看详细走势图
TradingKey Corcept Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Corcept Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名68/159位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价94.20。中期看，股价处于下降通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Corcept Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Corcept Therapeutics Inc亮点
亮点风险
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
业绩高增长
公司营业收入稳步增长，连续3年增长67.98%
利润高增长
公司净利润处于行业前列，最新年度总收入675.04M美元
估值合理
公司最新PE估值39.97，处于3年历史合理位
机构减仓
最新机构持股79.55M股，环比减少0.00%
乔尔·格林布拉特持仓
明星投资者乔尔·格林布拉特持仓，最新持仓市值17.36K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.34
分析师目标
根据
6
位分析师
持有
评级
94.200
目标均价
+134.74%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Corcept Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Corcept Therapeutics Inc简介
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
公司代码CORT
公司Corcept Therapeutics Inc
CEOBelanoff (Joseph K)
网址https://www.corcept.com/
相关品种
